PFKM and glioblastoma: In conclusion, using a comprehensive analysis of the glycolytic metabolism in several in vitro and in vivo GBM models, we show that glycolysis is a promising target for GBM therapy, especially though the specific inhibition of the enzymes PFK1 and PDK1.